Invesco Biotechnology & Genome ETF
PBE
PBE
89 hedge funds and large institutions have $63M invested in Invesco Biotechnology & Genome ETF in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 27 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
67% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 27
Holders
89
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$8.97M | |
| 2 | +$3.7M | |
| 3 | +$379K | |
| 4 |
SB
Strategic Blueprint
Atlanta,
Georgia
|
+$291K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$258K |
Top Sellers
| 1 | -$707K | |
| 2 | -$359K | |
| 3 | -$341K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$297K |
| 5 |
BCM
Beck Capital Management
Austin,
Texas
|
-$292K |